Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Acrux ( (AU:ACR) ).
Acrux Ltd has announced a change in the interest of its director, Don Brumley, who has increased his holdings by acquiring 448,334 ordinary shares through the exercise of vested unlisted rights issued in 2024. This change reflects a strategic move by the director to increase his stake in the company, potentially signaling confidence in Acrux’s future performance and aligning his interests more closely with those of the shareholders.
More about Acrux
Acrux Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative drug delivery solutions. The company primarily offers products that enhance the delivery of medications through the skin, targeting various therapeutic areas and aiming to improve patient outcomes.
Average Trading Volume: 271,212
Technical Sentiment Signal: Sell
Current Market Cap: A$9.78M
Find detailed analytics on ACR stock on TipRanks’ Stock Analysis page.